Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notice of Results and Investor Presentation
LONDON, 18 September 2023: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, will announce its results for the six months ended 30 June 2023 on Thursday 28 September 2023.
Analyst Briefing: 10.00am BST, Thursday 28 September 2023
Management will host a virtual analyst presentation followed by a Q&A session at 10.00am BST on Thursday 28 September 2023. Analysts wishing to join should register their interest by contacting celadon@powerscourt-group.com.
Investor Presentation: 3.30pm BST, Thursday 28 September 2023
Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 3.30pm BST on Thursday 28 September 2023.
The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
Investors who already follow Celadon on the Investor Meet Company platform will automatically receive an invitation to the event.
Enquiries:
| Celadon Pharmaceuticals Plc |
|
| James Short, CEO Arthur Wakeley, MD Jonathan Turner, CFO | Via Powerscourt |
|
|
|
| Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
| Bobbie Hilliam / Max Hartley | +44 (0)20 7523 8000 |
| | |
| Powerscourt Group | |
| Sarah MacLeod / Nick Johnson / Sam Austrums | +44 (0)20 7250 1446 celadon@powerscourt-group.com |
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its GMP pharmaceutical cannabis product. The Group owns an approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
